With promis­ing PhII blood dis­or­der da­ta in hand, Disc Med­i­cine seeks $100M in pub­lic of­fer­ing

Disc Med­i­cine is look­ing for even more cap­i­tal to fund its can­di­dates for blood dis­or­ders on the heels of a $62.5 mil­lion di­rect of­fer­ing and the first clin­i­cal ev­i­dence sup­port­ing its lead can­di­date.

The Wa­ter­town, MA, bio­phar­ma is of­fer­ing up $100 mil­lion worth of shares of its com­mon stock in an un­der­writ­ten pub­lic of­fer­ing, in which cer­tain in­vestors can go for pre-fund­ed war­rants in­stead. The un­der­writ­ers al­so get a 30-day op­tion to pur­chase up to an ad­di­tion­al $15 mil­lion of shares of its com­mon stock, the com­pa­ny said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER